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OBJECTIVE: This study was performed to evaluate the effects of metabolic parameters and thyroid dysfunction
on the development of non-alcoholic fatty liver disease (NAFLD).
METHODS: The current study evaluated a total of 115 patients, 75 female and 40 male. Physical examination
and anthropometric measurements were applied to all participants. Hypothyroidism was considered at a
thyroid stimulating hormone level X 4.1 mIU/L. Patients with euthyroidism and patients with hypothyroidism
were compared. Abdominal ultrasonography was used to diagnose non-alcoholic fatty liver disease. The
participants were further compared with regard to the presence of non-alcoholic fatty liver disease. Logistic
regression modeling was performed to identify the relationship between non-alcoholic fatty liver disease and
independent variables, such as metabolic parameters and insulin resistance.
RESULTS: Non-alcoholic fatty liver disease was identified in 69 patients. The mean waist circumference, body
mass index, fasting plasma insulin, HOMA-IR (po0.001) and FT3/FT4 ratio (p=0.01) values were significantly
higher in the patients with NAFLD compared to those without it. Multivariate regression analysis revealed
that FT3/FT4 ratio, waist circumference and insulin resistance were independent risk factors for non-alcoholic
fatty liver disease.
CONCLUSION: Insulin resistance, enlarged waist circumference, elevated body mass index, higher FT3/FT4 ratio
and hypertriglyceridemia are independent risk factors for NADLF, whereas hypothyroidism is not directly related
to the condition.
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’ INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), a pathological
spectrum of chronic liver diseases ranging from simple steatosis
to non-alcoholic steatohepatitis (NASH) with inflammation, has
a high risk for progression to cirrhosis (1-3). NAFLD is a
growing diagnosis and the most commonly encountered liver
pathology in clinical practice (4,5). NAFLD is commonly
asymptomatic and discovered incidentally. The diagnosis of
NAFLD is based on exclusion criteria, such as alcohol
consumption (more than 20 g/day), autoimmune liver disease,
viral hepatitis infection, hemochromatosis, Wilson’s disease,
and drug consumption. All of these must be excluded before
considering NAFLD (6). The prevalence of NAFLD is
associated with abdominal obesity, diabetes mellitus and other
metabolic risk factors (7, 8). NAFLD is a strong determinant for
the development of metabolic syndrome, which has potentially
relevant clinical implications with regard to diagnosis, preven-
tion and treatment (9,10). Moreover, metabolic syndrome,
insulin resistance, diabetes, obesity and mixed hyperlipidemia
are major metabolic risk factors for NAFLD (11). Because of the
hyperinsulinism, pro-thrombotic potential, and subclinical
inflammation associated with NAFLD, patients with this
condition are at increased risk for cardiovascular mortality
(12). In addition, the correction of insulin resistance may not be
sufficient to successfully treat NASH in the majority of patients,
conflicting with previous studies on NAFLD pathogenesis (13).
The thyroid gland is significantly involved in lipid and
carbohydrate metabolism, regulation of body weight and
adipogenesis (14). Recent studies have suggested that
thyroid dysfunction may play a role in NAFLD. Subclinical
hypothyroidism is associated with metabolic syndrome, cardi-
ovascular mortality, and disturbance of lipid metabolismDOI: 10.6061/clinics/2016(04)08
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(15, 16). Thyroid dysfunctions in the form of overt or subclinical
hypothyroidism are prevalent among patients with NAFLD/
NASH (17).
NAFLD is a risk factor for the development of type 2
diabetes, which is, in turn, a major contributor to progressive
liver disease (18). In contrast, chronic infections, such as that
caused by hepatitis C virus, have an association with the
development of NAFLD, insulin resistance and metabolic
parameters (19). The identification of risk factors is essential
for preventing NAFLD. Therefore, in the current study, we
evaluated the effects of metabolic parameters and thyroid
dysfunction on the development of NAFLD.
’ METHODS
Participants
The current study evaluated 115 individuals, 75 female and
40 male, who were admitted to the Haseki Training and
Research Hospital’s outpatient clinic for routine care from
July 2014 through January 2015. Anthropometric measure-
ments were taken, and thyroid function tests were performed.
Hypothyroidism was described according to Clinical Practice
Guidelines for Hypothyroidism in Adults: Cosponsored by
the American Association of Clinical Endocrinologists and the
American Thyroid Association (20). Euthyroidism (ET) was
described as a thyroid stimulating hormone (TSH) level of
0.5—4 mIU/L and no history of chronic disease. Hypothyroid-
ism (HT) was described as a TSH level of X 4.1 mIU/L.
Patients meeting the following criteria were excluded: chronic
liver and kidney disease, viral hepatitis, diabetes mellitus,
undergoing corticosteroid treatment, malignancy, alcohol
consumption greater than 20 g/d, and pregnancy. Informed
consent was obtained from all participants. The study protocol
was approved by the local ethics committee of Istanbul Haseki
Training and Research Hospital.
Measurements
All patients underwent physical examination. Blood pressure
was measured using a mercury sphygmomanometer. Height
(m), weight (kg), and waist circumference (WC) were also
measured. WC was measured between the lowest rib and the
crista iliaca superior. Body mass index (BMI) was calculated as
weight (kg)/height (m)2. Plasma TSH, free T3 (FT3), free T4
(FT4), alanine aminotransferase (ALT), aspartate alanine
aminotransferase (AST), gamma glutamyl transferase
(GGT), alkaline phosphatase (ALP), glucose, insulin, total
cholesterol, triglycerides, HDL and LDL cholesterol, uric acid
and creatinine were measured after an 8-hour fast using an
Abbot Architect Analyzer System (IL, USA). The home-
ostasis model assessment for insulin resistance (HOMA-IR)
was calculated using the following formula: fasting blood
glucose (mmol/l)  [insulin (mU/l)/22.5].
Abdominal Ultrasonography
The presence of qualitative steatosis was determined using a
standard 2D abdominal ultrasonography (USG). All partici-
pants underwent abdominal USG (Philips Active Array, 2D-
Clearvue 550 device). NAFLD was characterized by the
presence of hepatic brightness, hepatorenal echo contrast,
deep attenuation and vascular blurring on USG (21).
Statistical Analysis
Numeric values were expressed as the mean ± standard
deviation. Statistical analysis was performed using SPSS 16.0
for Windows. The Kolmogorov-Smirnov Z test was used to
determine the distributions of variables. Regular variances
were assessed using a t test, and irregular variables were
assessed using the Mann-Whitney U test. Logistic regression
modeling was performed to assess independent risk factors
of NAFLD. A p value o0.05 was considered statistically
significant.
’ RESULTS
In total, 115 participants were enrolled in this study:
54 presented with HT (F/M, 39/15) and 61 presented with
ET (F/M, 36/25). The anthropometric and metabolic para-
meters of the patients with ET and HTwere compared and are
presented in Table 1. No significant differences were found in
gender, age, mean BMI, systolic BP, diastolic BP, ALT, AST,
ALP, GGT, total cholesterol, triglycerides, LDL cholesterol,
HDL cholesterol, uric acid, fasting glucose, fasting insulin,
HOMA-IR, NAFLD or ferritin in the subjects with ET (30.28±
5.19) versus those with HT. The mean FT3/FT4 ratio of
the patients with HT was higher than that of the subjects
with ET, at 4.61 ± 1.38 versus 3.63 ± 0.68, respectively
(po0.001). There was no difference in NAFLD status
between the patients with ET and those with HT. NAFLD
was identified in 69 of total 115 subjects: 33 patients with
ET and 36 patients with HT.
The participants were compared according to the presence
of NAFLD, and the parameters of the comparison are
presented in Table 2. The mean WC, BMI, systolic and
diastolic blood pressure values were statistically higher in the
patients with NAFLD than those without the condition
(po0.001, o0.001, 0.049 and 0.003, respectively). Addition-
ally, the patients with NAFLD had significantly higher
triglyceride levels (164.96± 77.27 mg/dl) than those without
NAFLD (112.61± 89.80 mg/dl) (p=0.001). The patients with
NAFLD also had significantly higher uric acid, fasting
insulin, HOMA-IR and FT3/FT4 ratios.
The subjects with ET or HT in this study were also
compared according to the presence or absence of NAFLD, as
shown in Table 3. The patients with ET and NAFLD had
higher WC (p=0.001), total cholesterol (p=0.042), triglycerides
(po0.001), fasting insulin (po0.001) and HOMA-IR (p=0.001)
levels compared to the subjects with ET without NAFLD.
While the FT4 levels in the patients with ETand NAFLD were
lower than those in the patients with ETwithout NAFLD, the
patients with ET and NAFLD had increased FT3/FT4 ratios,
as well as uric acid, fasting insulin and HOMA-IR levels,
compared to the patients with ET without NAFLD (p=0.01).
The patients with HT and NAFLD had lower FT4 levels
compared to the patients with HTwithout NAFLD (Table 3).
Additionally, the patients with HT and NAFLD had
higher WC, total cholesterol, triglycerides, fasting insulin
and HOMA-IR levels than the patients with HT without
NAFLD.
Logistic regression analysis was performed to delineate the
nature of the relationships that exist between NAFLD,
metabolic parameters and insulin resistance as independent
variables (Table 4). WC (OR: 1.087, p=0.01), HOMA-IR (OR:
2.978, p=0.005), and FT3/FT4 ratio (OR: 1.834, p=0.02) were
independent risk factors for NAFLD in all study partici-
pants. Additional regression analysis was performed to
evaluate HT patients with NAFLD with respect to metabolic
parameters (Table 5). WC (OR: 1.189, p=0.02), triglycerides
(OR: 1.031, p=0.04), uric acid (OR: 0.318, p=0.03), HOMA-IR
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(OR: 8.042, p=0.02) and FT3/FT4 ratio (OR: 3.540, p=0.01) were
independent risk factors for NAFLD in patients with HT.
’ DISCUSSION
NAFLD is a burgeoning health problem and is currently
recognized as the most common metabolic liver disease.
Insulin resistance and obesity contribute to the development
of NAFLD, which has become the most prevalent liver
disease worldwide, affecting one-third of the global adult
population (22,23). NAFLD can lead to NASH and/or
hepatocellular cancer (24).
It has been suggested that a relationship exists between
NAFLD and thyroid dysfunction (25). Despite the precise
physiological mechanism underlying the development of
NAFLD, the relationship between NAFLD, hypothyroidism
and metabolic syndrome remains unclear. Because of the
importance of thyroid hormones in lipid metabolism (26), HT
may result in hyperlipidemia, thereby initiating the devel-
opment of NAFLD. Several studies have indicated that
hypothyroidism is a risk factor for NAFLD and can result in
metabolic syndrome (16,27,28). FT3/FT4 ratio can be con-
sidered an indicator of peripheral deiodinase activity. Bilgin
and Pirgon (29) suggested that augmented conversion from
FT4 to FT3 due to increased deiodinase activity is a
compensatory mechanism for fat accumulation to improve
energy expenditure. FT3/FT4 ratio positively correlates with
HOMA-IR in patients with NAFLD (18). Moreover, positive
associations have been reported between FT3/FT4 ratio and
both waist circumference and BMI in patients with obesity
(30). Ittermann and Haring (31) reported that low FT4 levels,
but not low TSH and FT3 levels, are associated with hepatic
steatosis. In the present study, the mean BMI values in
patients with ETand patients with HTwere similar; however,
the patients with HT had significantly higher FT3/FT4 ratios
(po0.001). The patients with NAFLD had significantly
elevated BMI, WC, HOMA-IR values and FT3/FT4 ratios;
their FT4 levels were low, leading to increased FT3/FT4
ratios, but their TSH levels were unaffected. The results of
this study suggest that elevated FT3/FT4 ratio is an
independent risk factor for NAFLD.
Patients with HT have elevated triglyceride and LDL
cholesterol levels due to decreased plasma lipoprotein lipase
activity. Hyperlipidemia associated with fatty accumulation in
the liver and cellular oxidative stress is one potential mechan-
ism underlying the development of NAFLD (32,33). The results
of the present study support this relationship, as TC (p=0.002),
LDL cholesterol (p=0.001), triglyceride (p=0.008), and uric acid
(p=0.006) levels were significantly higher and HDL cholesterol
levels lower (p=0.022) in the patients with NAFLD.
The prevalence of NAFLD did not significantly differ between
the ET (n:36, 59%) and HT (n:33, 64%) groups. Mazo and Lima
(34) previously reported that no association exists between
HT, hepatosteatosis and NASH. In addition, Eshraghian and
Dabbaghmanesh (35) reported that no association exists between
autoimmune thyroid disorder and elevated anti-thyroid perox-
idase levels, anti-tiroglobulin levels and NAFLD. Furthermore,
NAFLD was not correlated with thyroid dysfunction in the
current study, as the included patients with ET and HT did not
show significant differences in NAFLD prevalence, insulin
resistance, abdominal obesity or BMI. The mean BMI of the
patients with ET and HTwas above 30, and abdominal obesity
was considered to be more important to the development of
NAFLD than HT. WC, FT3/FT4 ratio, triglyceride level and
serum uric acid level were independent risk factors for
Table 1 - Parameters compared between patients with euthyroidism
and those with hypothyroidism.
Parameters Patients with ET
(n:61)
Patients with
HT (n:54)
p value
Gender, male % 41% 27.8% 0.138
Age 48.44 ± 13.19 47.98 ± 11.87 0.845
WC (cm) 94.34 ± 11.00 92.11 ± 12.59 0.312
BMI 30.28 ± 5.19 30.05 ± 6.54 0.831
Systolic BP (mm/Hg) 123.20 ± 18.14 118.24 ± 18.14 0.162
Diastolic BP (mm/Hg) 77.05 ± 11.45 73.61 ± 11.30 0.109
TSH (mIU/L) 1.63 ± 0.91 22.48 ± 15.91 o0.001
FT3 (pg/ml) 0.86 ± 0.11 0.62 ± 0.17 o0.001
FT4 (ng/dl) 3.07 ± 0.44 2.66 ± 0.37 o0.001
FT3/FT4 ratio 3.63 ± 0.68 4.61 ± 1.48 o0.001
ALT (mg/dl) 24.64 ± 15.67 21.76 ± 11.53 0.261
AST (mg/dl) 24.98 ± 8.14 24.37 ± 9.87 0.719
ALP (mg/dl) 79.96 ± 24.51 86.11 ± 28.26 0.22
GGT (mg/dl) 28.96 ± 20.42 28.40 ± 25.46 0.896
Total cholesterol (mg/dl) 203.77 ± 48.74 208.19 ± 43.87 0.613
Triglycerides (mg/dl) 131.11 ± 88.01 158.59 ± 82.20 0.088
LDL cholesterol (mg/dl) 127.92 ± 39.25 126.83 ± 36.89 0.879
HDL cholesterol (mg/dl) 51.04 ± 9.97 49.66 ± 11.05 0.484
Uric acid (mg/dl) 5.10 ± 1.40 4.96 ± 1.54 0.705
Fasting glucose (mg/dl) 99.69 ± 21.04 103.41 ± 39.09 0.52
Fasting insulin (mIU/ml) 8.83 ± 5.23 8.59 ± 4.87 0.804
HOMA-IR 2.15 ± 1.32 2.11 ± 1.26 0.894
NAFLD (n - %) 36 - 59% 33 - 64% 0.819
Ferritin (ng/ml) 61.79 ± 91.20 29.12 ± 18.77 0.099
Euthyroidism, hypothyroidism n: number of patients. WC: waist circum-
ference. BMI: body mass index. BP: blood pressure. ALT: alanine aminotrans-
ferase. AST: aspartate aminotransferase. ALP: alkaline phosphatase. GGT:
gamma glutamyl transferase. HOMA-IR: homeostasis model assessment for
insulin resistance. NAFLD: non-alcoholic fatty liver disease.
Table 2 - Comparison of study parameters between patients
with and without non-alcoholic fatty liver disease.
Parameters Without NAFLD
(n:46)
With NAFLD
(n:69)
p value
Gender, male % 28.3% 39.1% 0.231
Age 45.76 ± 12.30 49.87 ± 12.51 0.085
WC (cm) 86.20 ± 12.73 98.03 ± 8.27 o0.001
BMI 27.11 ± 5.29 32.21 ± 5.30 o0.001
Systolic BP (mm/Hg) 116.63 ± 17.80 123.70 ± 19.24 0.049
Diastolic BP (mm/Hg) 71.63 ± 9.95 77.97 ± 11.77 0.003
TSH (mIU/L) 9.51 ± 10.33 13.81 ± 20.30 0.138
FT3 (pg/ml) 2.91 ± 0.34 2.85 ± 0.52 0.479
FT4 (ng/dl) 0.80 ± 0.16 0.72 ± 0.20 0.025
FT3/FT4 ratio 3.78 ± 0.82 4.32 ± 1.42 0.015
ALT (mg/dl) 18.02 ± 9.34 26.80 ± 15.32 o0.001
AST (mg/dl) 21.62 ± 5.87 26.74 ± 10.05 0.001
ALP (mg/dl) 79.46 ± 24.38 84.98 ± 27.54 0.28
GGT (mg/dl) 21.97 ± 18.29 33.15 ± 24.43 0.01
Total cholesterol (mg/dl) 189.89 ± 42.22 216.48 ± 46.23 0.002
Triglycerides (mg/dl) 112.61 ± 89.80 164.96 ± 77.27 0.001
LDL cholesterol (mg/dl) 115.93 ± 33.98 135.06 ± 38.83 0.008
HDL cholesterol (mg/dl) 53.22 ± 11.41 48.50 ± 9.41 0.022
Uric acid (mg/dl) 4.58 ± 1.46 5.36 ± 1.40 0.006
Fasting glucose (mg/dl) 102.17 ± 46.61 100.94 ± 12.20 0.862
Fasting insulin (mIU/ml) 5.72 ± 2.30 10.58 ± 5.38 o0.001
HOMA-IR 1.37 ± 0.60 2.62 ± 1.36 o0.001
Ferritin (ng/ml) 23.83 ± 12.62 54.80 ± 79.08 0.187
Non-alcoholic fatty liver disease. WC: waist circumference. BMI: body mass
index. BP: blood pressure. ALT: alanine aminotransferase. AST: aspartate
aminotransferase. ALP: alkaline phosphatase. GGT: gamma glutamyl trans-
ferase. HOMA-IR: homeostasis model assessment for insulin resistance.
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NAFLD in the patients with HT in our study. Abdominal
obesity is a substantial component of metabolic syndrome
and increases the risk for cardiovascular events. Visceral
fat can be considered an important predictive factor for
NAFLD (36).
The mean WC (po0.001), BMI (po0.001), systolic and
diastolic blood pressure (p=0.049 and p=0.003) values were
higher in the patients with NAFLD in the present study.
Fatty liver disease has been associated with anthropometric
findings. Moreover, abdominal obesity and increased WC
have been associated with NAFLD (37). Huang and Beilin
(38) demonstrated that systolic and diastolic blood pres-
sure are elevated in patients with NAFLD compared to
controls. Concordant with the referenced results, in the
current study, AST, ALT and GGT were increased in
patients with NAFLD. Chung and Kim (25) reported that
both the prevalence of NAFLD and ALT levels were higher
in patients with HT. Serum ALT level is a surrogate marker
for NAFLD in the absence of other causes of liver disease
(17). In the current study, fasting insulin and HOMA-IR
values were elevated in patients with NAFLD. Further-
more, insulin resistance and fasting insulin level formed
a strong relationship with NAFLD, independent of
HT. Additionally, it has been reported that hyperinsuline-
mia and HT can separately result in the development of
NAFLD (39,40).
In the current study, abdominal USG was applied to
diagnose NAFLD via the qualitative detection of steatosis.
Abdominal USG detects changes in fatty accumulation in the
liver of as low as X20% and closely mirrors coronary and
carotid atherosclerosis burden. In contrast, semi-quantitative
USG indices (to exclude NASH) and sonoelastography (to
Table 3 - Comparison of parameters between patients with ET or HT according to presence or absence of non-alcoholic fatty liver
disease.
Parameters with NAFLD without NAFLD p value
N 36 25 -
Age 49.78 ± 12.77 46.52 ± 13.80 0.347
Patients FT3 (pg/ml) 3.09 ± 0.52 3.04 ± 0.29 0.645
with FT4 (ng/dl) 0.84 ± 0.11 0.90 ± 0.10 0.046
euthyroidism FT3/FT4 ratio 3.78 ± 0.78 3.42 ± 0.47 0.01
TSH (mIU/L) 1.71 ± 0.96 1.50 ± 0.83 0.381
WC (cm) 98.86 ± 7.69 87.84 ± 11.90 o0.001
Total cholesterol (mg/dl) 215.25 ± 51.83 187.24 ± 39.20 0.026
LDL cholesterol (mg/dl) 137.56 ± 41.72 114.04 ± 31.18 0.02
HDL cholesterol (mg/dl) 49.06 ± 8.21 53.88 ± 11.65 0.082
Triglycerides (mg/dl) 143.72 ± 66.64 112.96 ± 110.93 0.18
Glucose (mg/dl) 101.97 ± 11.69 96.40 ± 29.79 0.313
Uric acid (mg/dl) 5.50 ± 1.42 4.48 ± 1.15 0.006
Fasting insulin (mIU/ml) 10.53 ± 5.82 6.05 ± 2.14 o0.001
HOMA-IR 2.62 ± 1.43 1.39 ± 0.53 o0.001
N 33 21 -
Age 49.97 ± 12.42 44.86 ± 10.48 0.124
Patients FT3 (pg/ml) 27.01 ± 23.02 19.04 ± 79 0.075
with FT4 (ng/dl) 2.59 ± 0.37 2.76 ± 0.35 0.103
hypothyroidism FT3/FT4 ratio 0.59 ± 0.19 0.68 ± 0.13 0.036
TSH (mIU/L) 4.89 ± 1.72 4.20 ± 0.94 0.27
WC (cm) 97.12 ± 8.89 84.24 ± 13.67 0.001
Total cholesterol (mg/dl) 217.82 ± 40.00 193.05 ± 46.34 0.042
LDL cholesterol (mg/dl) 132.33 ± 35.85 118.19 ± 37.69 0.172
HDL cholesterol (mg/dl) 47.89 ± 10.64 52.43 ± 11.34 0.14
Triglycerides (mg/dl) 188.12 ± 82.28 112.19 ± 58.08 o0.001
Glucose (mg/dl) 109.05 ± 61.09 99.82 ± 12.81 0.502
Uric acid (mg/dl) 5.19 ± 1.38 4.70 ± 1.76 0.259
Fasting insulin (mIU/ml) 10.64 ± 4.94 5.38 ± 2.44 o0.001
HOMA-IR 2.61 ± 1.30 1.34 ± 0.67 o0.001
NAFLD: non-alcoholic fatty liver disease. FT3: free T3. FT4: free T4. TSH: thyroid stimulating hormone. WC: waist circumference. HOMA-IR: homeostasis
model assessment for insulin resistance.
Table 4 - Logistic regression analysis of the association between
non-alcoholic fatty liver disease and metabolic variables in all
participants.
Variables p value OR 95% CI
WC 0.01 1.087 1.018 - 1.061
Triglycerides 0.12 1.010 0.997 - 1.031
Total cholesterol 0.21 1.009 0.995 - 0.921
Uric acid 0.79 1.056 0.706 - 51.283
HOMA-IR 0.005 2.978 1.397 - 9.575
FT3/FT4 ratio 0.02 1.834 1.089 - 3.569
WC: waist circumference. HOMA-IR: homeostasis model assessment for
insulin resistance. OR: odds ratio. CI: confidence interval.
Table 5 - Logistic regression analysis of the association between
non-alcoholic fatty liver disease and metabolic variables in patients
with HT.
Variables p value OR 95% CI
WC 0.02 1.189 1.024 - 1.381
Triglycerides 0.04 1.031 1.001 - 1.061
Total cholesterol 0.78 1.004 0.977 - 1.031
Uric acid 0.03 0.318 0.11 - 0.921
HOMA-IR 0.02 8.042 1.261 - 51.283
FT3/FT4 ratio 0.01 3.540 1.309 - 9.575
WC: waist circumference. HOMA-IR: homeostasis model assessment for
insulin resistance. OR: odds ratio. CI: confidence interval.
224
FT3/FT4 Ratio and NAFLD
Go¨kmen FY et al.
CLINICS 2016;71(4):221-225
quantify fibrosis) help predict liver histology and can be
used to help select patients to submit to liver biopsy (41).
According to the above, semi-quantitative steatosis indices
must be further investigated.
In conclusion, FT3/FT4 ratio, HOMA-IR and WC are risk
factors for the development of NAFLD. FT3/FT4 ratio is a
predictor of NAFLD independent of insulin resistance both
in patients with ET and in patients with HT. Elevated serum
triglyceride and uric acid levels are independent risk factors
for NAFLD in patients with HT.
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